TCR2 Therapeutics (TCRR) Collaborates with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo and Yervoy in Mesothelin-Expressing Solid Tumors
Go back to TCR2 Therapeutics (TCRR) Collaborates with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo and Yervoy in Mesothelin-Expressing Solid Tumors| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 54.00 -1.28 (2.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.28 | 52 Week High | $77.12 | |||
| Open | $55.20 | 52 Week Low | $49.03 | |||
| Day High | $55.33 | P/E | 35.06 | |||
| Day Low | $53.44 | EPS | $1.54 | |||
| Volume | 31,700,384 | |||||
| (NASDAQ: TCRR) | Delayed: 1.48 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.48 | 52 Week High | $ | |||
| Open | $3.63 | 52 Week Low | $ | |||
| Day High | $1.48 | P/E | N/A | |||
| Day Low | $1.48 | EPS | $ | |||
| Volume | 52,452 | |||||
